A Phase 2, Multi-center, Vehicle- and Sham-controlled, Randomized Study of RESTASIS X in Patients With Moderate to Severe Dry Eye Disease
Phase of Trial: Phase II
Latest Information Update: 23 May 2018
Price : $35 *
At a glance
- Drugs Ciclosporin (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Allergan
- 20 Dec 2017 Status changed from recruiting to discontinued.
- 26 Jul 2017 Planned number of patients changed from 146 to 32.
- 26 Jul 2017 Planned End Date changed from 1 Jul 2018 to 1 Apr 2019.